---
title: "FDA Tissue Inspections: What Subpart F Allows In 2026"
description: "FDA tissue inspections explained: what 21 CFR 1271 Subpart F lets FDA do at a tissue establishment, from entry and records to retention and destruction orders."
url: "https://savemyfat.com/fda-tissue-inspections-subpart-f/"
---

# FDA Tissue Establishment Inspections: What Part 1271 Subpart F Lets FDA Do

Table of Contents

- [Oscar Tellez](https://savemyfat.com/oscar-tellez/)
- October 12, 2026
- 10:00 am
- [Regulation](https://savemyfat.com/category/regulation/)

![Tissue processing lab with a biosafety cabinet and an audit binder, the space examined in fda tissue inspections](https://savemyfat.com/wp-content/uploads/2026/09/fda-tissue-inspections-subpart-f.webp)Fda tissue establishment inspections: what part 1271 subpart f lets fda do 2

A bank’s website says it is “FDA registered,” and the next question is whether FDA ever walks through the door. This guide explains Subpart F of 21 CFR Part 1271, the inspection and enforcement part of the tissue rule. It covers when FDA tissue inspections can happen, what FDA can look at, what it can order, and why none of that is approval of any use of banked adipose tissue.

**TLDR Subpart F of Part 1271 lets FDA inspect any establishment that manufactures HCT/Ps at any reasonable time, with or without notice, review and copy required records, and take samples. Under section 1271.440 it can order retention, recall, destruction, or a stop to manufacturing. Registration is a listing, inspection is oversight, and neither is approval of any product or use. Banking adipose tissue does not guarantee access to any future therapy.**

**Important Disclaimer:** Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any condition. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.

---

Registered sounds like checked, and checked sounds like approved. Neither jump is correct, and the difference matters when your own tissue is what is being stored.

How to check whether a bank is legitimate is one of the questions readers bring to this site most often. Part of the answer sits in Subpart F, which spells out the FDA tissue inspections and orders that registration exposes an establishment to. This post does not say whether any particular bank, including our laboratory partner, has been inspected or what any inspection found. Save My Fat connects patients and providers with a U.S. tissue bank and does not itself collect, process, store, or treat tissue.

## What Is Subpart F of Part 1271?

Subpart F is the inspection and enforcement subpart of 21 CFR Part 1271, the federal rule for human cells and tissues, or HCT/Ps. Three sections do the work: 1271.400 on inspections, 1271.420 on imports, and 1271.440 on orders of retention, recall, destruction, and cessation. The rest of Part 1271 tells an establishment what it must do. Subpart F tells FDA what it may do when it wants to check.

Part 1271 addresses communicable disease, not clinical value. Every Subpart F power is aimed at whether an establishment’s controls keep disease out of the tissue, not at whether stored tissue will ever be useful to the person who banked it.

The scope is broad. Under [section 1271.1](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.1), an establishment that manufactures 361 HCT/Ps must register and list with FDA and comply with the part “whether or not the HCT/P enters into interstate commerce.” A bank serving only its own state is still inside Subpart F. Our guide to [FDA establishment registration](https://savemyfat.com/fda-establishment-registration-for-hct-p-providers/) explains that first step.

---

## When Can FDA Tissue Inspections Happen?

FDA tissue inspections can happen at any reasonable time, in a reasonable manner, with or without prior notice, at any location where HCT/Ps are manufactured. [Section 1271.400](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-F/section-1271.400) states that “the inspection may be made with or without prior notification and will ordinarily be made during regular business hours.”

There is no fixed schedule. Section 1271.400(b) says “the frequency of inspection will be at the agency’s discretion.” A bank cannot tell you when FDA will next appear, and a bank that has never been inspected is not out of compliance for that reason.

“Manufacturing” is wider than it sounds. Under [section 1271.150](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-D/section-1271.150), current good tissue practice governs “all steps in recovery, donor screening, donor testing, processing, storage, labeling, packaging, and distribution.” Storage is manufacturing, so a freezer room is a location FDA may inspect. Our explainer on [good tissue practice](https://savemyfat.com/current-good-tissue-practice-cgpt-fda-standard-lab/) covers those steps.

---

## What Can FDA Look At and Copy During an Inspection?

During an inspection FDA may examine the establishment, its facilities, equipment, materials, containers, processes, HCT/Ps, procedures, labeling, records, and controls. That list comes from section 1271.400(a). Section 1271.400(d) adds that FDA may take samples and “may review and copy any records required to be kept under this part.”

Records give an inspection teeth. Under [section 1271.270](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-D/section-1271.270), required records must be concurrent, accurate, indelible, and legible, must identify who did the work and when, and must be kept for at least 10 years. Section 1271.270(e) adds that the names and responsibilities of any contractors “must be available during an inspection conducted under section 1271.400.”

---

## What Orders Can FDA Issue Under Section 1271.440?

Under [section 1271.440](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-F/section-1271.440), when FDA has reasonable grounds to believe an HCT/P is violative, infected, or contaminated, or that an establishment is violating Part 1271, it may order the HCT/P retained, recalled, or destroyed, take possession of it, or order the establishment to stop manufacturing. FDA may “serve upon the person who distributed the HCT/P a written order that the HCT/P be recalled and/or destroyed, as appropriate.”

Orders must state the facts with particularity. Recall or destruction is ordinarily carried out within 5 working days, and an establishment that wants a hearing must request one within 5 working days of receiving the order. Cessation takes effect immediately if FDA finds a danger to health, and otherwise after 5 working days or the hearing decision.

Under [section 1271.420](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-F/section-1271.420), an imported HCT/P “must be held intact by the importer or consignee, under conditions necessary to prevent transmission of communicable disease, until an admissibility decision is made by FDA.” The table sorts the three sections.

Section What it lets FDA do Trigger in the rule

1271.400 Inspections Enter any manufacturing location at a reasonable time, with or without notice; examine facilities, records, and HCT/Ps; take samples; copy required records Any registered establishment, as often as FDA chooses

1271.420 Imports Require notice to the FDA district at the port of entry; hold the HCT/P intact, or under quarantine, until an admissibility decision An HCT/P offered for import

1271.440 Orders Order retention, recall, or destruction in writing; take possession; order cessation of manufacturing; hearing request due within 5 working days Reasonable grounds of a violative, infected, or contaminated HCT/P, or a Part 1271 violation

Every row is a power FDA holds over a registered bank, and none is a statement about the tissue’s future usefulness.

---

## Why Is Registration Not Approval?

Registration is a listing, inspection is oversight, and approval of a product for a use is a separate process that neither one triggers. Registering and listing under section 1271.1 puts an establishment on FDA’s map and inside Subpart F. FDA reviews no evidence that the tissue works for anything.

No adipose-derived stem cell product currently has FDA approval for any condition. A bank can be registered, pass an inspection, and keep flawless records, and none of that changes the regulatory status of the tissue in the freezer. Our post on [adipose tissue regulations](https://savemyfat.com/understanding-fda-regulations-for-adipose-tissue/) explains how Part 1271 sorts tissue products.

---

## What Can a Patient Ask a Bank About FDA Tissue Inspections?

A patient can ask a bank, in writing, whether FDA has inspected the establishment, when the last inspection took place, whether FDA issued a Form 483 or a warning letter afterward, and how the bank handles deviations from its procedures. Section 1271.400 lets FDA look for those answers on site, and nothing stops you from asking directly.

Ask for the establishment’s legal name as it appears in its FDA registration, because inspections and orders attach to establishments, not to brands or websites. If the bank uses a contractor, section 1271.270(e) means those names must be available to FDA, so ask for them too. Our guide to [FDA warning letters](https://savemyfat.com/fda-warning-letters-in-regenerative-medicine/) explains how to read a letter if one exists.

Inspection history, including our laboratory partner’s, is a question for the establishment that holds your tissue.

---

## Frequently Asked Questions

### Does “FDA registered” mean FDA has inspected the bank?

No. Registration under section 1271.1 is a listing with FDA. Section 1271.400 gives FDA the right to inspect, with or without notice, but the frequency is at the agency’s discretion.

### Can FDA order a bank to destroy stored tissue?

Yes, under section 1271.440, if FDA has reasonable grounds to believe an HCT/P is violative, infected, or contaminated, or that the establishment is violating Part 1271. The order must state the facts with particularity, and the establishment may request a hearing within 5 working days.

### Does passing FDA tissue inspections mean my banked fat will be usable in a future therapy?

No. Inspections check facilities, records, and controls against Part 1271, which addresses communicable disease. No adipose-derived stem cell product currently has FDA approval for any condition, and banking does not guarantee eligibility for any trial or program. Any future use depends on regulatory status at that time and your own licensed healthcare professionals.

---

## Key Takeaways

Subpart F of Part 1271 is where FDA’s power over a tissue establishment lives. Section 1271.400 lets FDA inspect any manufacturing location at a reasonable time, with or without notice, take samples, and copy required records, as often as it chooses. Section 1271.440 lets it order retention, recall, destruction, or cessation on reasonable grounds, with a hearing request due within 5 working days. Registration is a listing and inspection is oversight. Neither is approval of any product or use, and neither says whether banked adipose tissue will ever be used.

Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.

Readers weighing adipose tissue banking for potential future use can review [current pricing](https://savemyfat.com/pricing/) or bring their inspection questions to the [contact page](https://savemyfat.com/contact-us/).

---

*Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.*

*This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about treatment or research participation.*

**About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

**Related guide:** [FDA adipose tissue regulation](https://savemyfat.com/fda-regulation-adipose-tissue/).

Follow Save My Fat on Google

Set us as a preferred source and Google will show our latest updates more often in your results.

[PrevPreviousMoving Banked Tissue to Another Bank: Transfer, Release, and the Paperwork](https://savemyfat.com/banked-tissue-transfer-guide/)

[NextCalifornia Tissue Bank Licensing: What Health and Safety Code 1635 RequiresNext](https://savemyfat.com/california-tissue-bank-license-hsc-1635/)

Adipose Banking

### [What Happens to Banked Tissue If You Die: Next of Kin, Directives, and the Storage Agreement](https://savemyfat.com/banked-tissue-succession-planning/)

 [Read More »](https://savemyfat.com/banked-tissue-succession-planning/)

Oscar Tellez 10/22/2026 10:00 AM

Regulation

### [FDA’s Tissue Reference Group: Who Decides Whether a Tissue Product Is 361 or 351](https://savemyfat.com/tissue-reference-group-fda-361-351/)

 [Read More »](https://savemyfat.com/tissue-reference-group-fda-361-351/)

Oscar Tellez 10/21/2026 10:00 AM

Adipose Banking

### [Cord Blood Banking vs Adipose Banking: What Applies to You as an Adult](https://savemyfat.com/cord-blood-vs-adipose-banking/)

 [Read More »](https://savemyfat.com/cord-blood-vs-adipose-banking/)

Oscar Tellez 10/20/2026 10:00 AM

Regulation

### [FDA’s 2026 Plausible Mechanism Draft Guidance: What It Could Mean for Autologous Cells](https://savemyfat.com/plausible-mechanism-guidance-fda-2026/)

 [Read More »](https://savemyfat.com/plausible-mechanism-guidance-fda-2026/)

Oscar Tellez 10/19/2026 10:00 AM

Regulation

### [Tissue Recalls: How an HCT/P Recall Works and What It Would Mean for Banked Tissue](https://savemyfat.com/tissue-recall-hctp-banked-tissue/)

 [Read More »](https://savemyfat.com/tissue-recall-hctp-banked-tissue/)

Oscar Tellez 10/16/2026 10:00 AM

Regulation

### [Which States License Tissue Banks, and Why It Matters for Your Banked Tissue](https://savemyfat.com/tissue-bank-licensing-by-state/)

 [Read More »](https://savemyfat.com/tissue-bank-licensing-by-state/)

Oscar Tellez 10/15/2026 10:00 AM

```json
[{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/regulation\/","name":"Regulation"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/","name":"FDA Tissue Establishment Inspections: What Part 1271 Subpart F Lets FDA Do"}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of Save My Fat, a company that connects patients and physicians with a U.S. tissue bank for adipose tissue banking, so a person's own tissue can be preserved for potential future use in FDA-regulated pathways. He is not a physician.","url":"https:\/\/savemyfat.com\/oscar-tellez\/","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Cryopreservation","Regenerative Medicine Regulation","Adipose-Derived Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez\/","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","@id":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/#article","headline":"FDA Tissue Establishment Inspections: What Part 1271 Subpart F Lets FDA Do","url":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/"},"datePublished":"2026-10-12T10:00:00-04:00","dateModified":"2026-10-11T15:59:13-04:00","description":"FDA tissue inspections explained: what 21 CFR 1271 Subpart F lets FDA do at a tissue establishment, from entry and records to retention and destruction orders.","inLanguage":"en-US","articleSection":"Fda Tissue Inspections Subpart F","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez\/"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","url":"https:\/\/savemyfat.com"},"image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/09\/fda-tissue-inspections-subpart-f.webp"},{"@type":"FAQPage","@id":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/#faq","inLanguage":"en-US","mainEntity":[{"@type":"Question","name":"Does \u201cFDA registered\u201d mean FDA has inspected the bank?","acceptedAnswer":{"@type":"Answer","text":"No. Registration under section 1271.1 is a listing with FDA. Section 1271.400 gives FDA the right to inspect, with or without notice, but the frequency is at the agency\u2019s discretion."}},{"@type":"Question","name":"Can FDA order a bank to destroy stored tissue?","acceptedAnswer":{"@type":"Answer","text":"Yes, under section 1271.440, if FDA has reasonable grounds to believe an HCT\/P is violative, infected, or contaminated, or that the establishment is violating Part 1271. The order must state the facts with particularity, and the establishment may request a hearing within 5 working days."}},{"@type":"Question","name":"Does passing FDA tissue inspections mean my banked fat will be usable in a future therapy?","acceptedAnswer":{"@type":"Answer","text":"No. Inspections check facilities, records, and controls against Part 1271, which addresses communicable disease. No adipose-derived stem cell product currently has FDA approval for any condition, and banking does not guarantee eligibility for any trial or program. Any future use depends on regulatory status at that time and your own licensed healthcare professionals."}}]}]},{"@context":"https:\/\/schema.org","@type":"WebPage","@id":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/#webpage","url":"https:\/\/savemyfat.com\/fda-tissue-inspections-subpart-f\/","name":"FDA Tissue Inspections: What Subpart F Allows in 2026","speakable":{"@type":"SpeakableSpecification","cssSelector":[".smf-speakable"]}}]
```